Clinical Trials
22 trialsNCT01231412 2026-04-30
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 3 Completed
NCT01203722 2026-02-19
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT03159702 2026-01-27
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Medical College of Wisconsin
Phase 2 Completed
NCT04395222 2026-01-06
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT01349101 2025-12-15
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
Thomas Jefferson University
Phase 2 Completed
NCT05579769 2025-10-02
Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01810588 2025-09-02
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT01350258 2025-05-31
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Thomas Jefferson University
Phase 1/2 Terminated
NCT00429143 2025-05-04
A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative
Thomas Jefferson University
Phase 1/2 Completed
NCT01532635 2025-05-04
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Thomas Jefferson University
Phase 2 Terminated
NCT01341301 2025-04-30
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
Thomas Jefferson University
Phase 2 Completed
NCT01982682 2025-04-30
Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
Thomas Jefferson University
Phase 2 Completed
NCT04083170 2025-01-01
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT00603954 2022-01-26
Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings
University of Liege
Phase 2 Completed
NCT01749293 2020-02-25
Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation
University of Illinois at Chicago
Phase 2 Terminated
NCT01251575 2019-12-09
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00796562 2019-03-14
Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00185614 2018-01-18
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma
Stanford University
Phase 2 Completed
NCT00049504 2017-05-17
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00075478 2017-05-15
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Phase 3 Completed
NCT00402714 2017-01-18
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
Yale University
Phase 2 Completed
NCT00058825 2016-11-07
HIMSUM
Baylor College of Medicine
Phase 1/2 Terminated